Cargando…
Antigenicity and receptor-binding ability of recombinant SARS coronavirus spike protein
Severe acute respiratory syndrome (SARS) is an emerging infectious disease associated with a novel coronavirus and causing worldwide outbreaks. SARS coronavirus (SARS-CoV) is an enveloped RNA virus, which contains several structural proteins. Among these proteins, spike (S) protein is responsible fo...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc.
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7111049/ https://www.ncbi.nlm.nih.gov/pubmed/14706633 http://dx.doi.org/10.1016/j.bbrc.2003.11.180 |
_version_ | 1783513193395519488 |
---|---|
author | Ho, Tin-Yun Wu, Shih-Lu Cheng, Shin-Ei Wei, Yen-Chiao Huang, Shan-Ping Hsiang, Chien-Yun |
author_facet | Ho, Tin-Yun Wu, Shih-Lu Cheng, Shin-Ei Wei, Yen-Chiao Huang, Shan-Ping Hsiang, Chien-Yun |
author_sort | Ho, Tin-Yun |
collection | PubMed |
description | Severe acute respiratory syndrome (SARS) is an emerging infectious disease associated with a novel coronavirus and causing worldwide outbreaks. SARS coronavirus (SARS-CoV) is an enveloped RNA virus, which contains several structural proteins. Among these proteins, spike (S) protein is responsible for binding to specific cellular receptors and is a major antigenic determinant, which induces neutralizing antibody. In order to analyze the antigenicity and receptor-binding ability of SARS-CoV S protein, we expressed the S protein in Escherichia coli using a pET expression vector. After the isopropyl-β-d-thiogalactoside induction, S protein was expressed in the soluble form and purified by nickel-affinity chromatography to homogeneity. The amount of S protein recovered was 0.2–0.3 mg/100 ml bacterial culture. The S protein was recognized by sera from SARS patients by ELISA and Western blot, which indicated that recombinant S protein retained its antigenicity. By biotinylated ELISA and Western blot using biotin-labeled S protein as the probe, we identified 130-kDa and 140-kDa proteins in Vero cells that might be the cellular receptors responsible for SARS-CoV infection. Taken together, these results suggested that recombinant S protein exhibited the antigenicity and receptor-binding ability, and it could be a good candidate for further developing SARS vaccine and anti-SARS therapy. |
format | Online Article Text |
id | pubmed-7111049 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2004 |
publisher | Published by Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71110492020-04-02 Antigenicity and receptor-binding ability of recombinant SARS coronavirus spike protein Ho, Tin-Yun Wu, Shih-Lu Cheng, Shin-Ei Wei, Yen-Chiao Huang, Shan-Ping Hsiang, Chien-Yun Biochem Biophys Res Commun Article Severe acute respiratory syndrome (SARS) is an emerging infectious disease associated with a novel coronavirus and causing worldwide outbreaks. SARS coronavirus (SARS-CoV) is an enveloped RNA virus, which contains several structural proteins. Among these proteins, spike (S) protein is responsible for binding to specific cellular receptors and is a major antigenic determinant, which induces neutralizing antibody. In order to analyze the antigenicity and receptor-binding ability of SARS-CoV S protein, we expressed the S protein in Escherichia coli using a pET expression vector. After the isopropyl-β-d-thiogalactoside induction, S protein was expressed in the soluble form and purified by nickel-affinity chromatography to homogeneity. The amount of S protein recovered was 0.2–0.3 mg/100 ml bacterial culture. The S protein was recognized by sera from SARS patients by ELISA and Western blot, which indicated that recombinant S protein retained its antigenicity. By biotinylated ELISA and Western blot using biotin-labeled S protein as the probe, we identified 130-kDa and 140-kDa proteins in Vero cells that might be the cellular receptors responsible for SARS-CoV infection. Taken together, these results suggested that recombinant S protein exhibited the antigenicity and receptor-binding ability, and it could be a good candidate for further developing SARS vaccine and anti-SARS therapy. Published by Elsevier Inc. 2004-01-23 2003-12-29 /pmc/articles/PMC7111049/ /pubmed/14706633 http://dx.doi.org/10.1016/j.bbrc.2003.11.180 Text en Copyright © 2003 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Ho, Tin-Yun Wu, Shih-Lu Cheng, Shin-Ei Wei, Yen-Chiao Huang, Shan-Ping Hsiang, Chien-Yun Antigenicity and receptor-binding ability of recombinant SARS coronavirus spike protein |
title | Antigenicity and receptor-binding ability of recombinant SARS coronavirus spike protein |
title_full | Antigenicity and receptor-binding ability of recombinant SARS coronavirus spike protein |
title_fullStr | Antigenicity and receptor-binding ability of recombinant SARS coronavirus spike protein |
title_full_unstemmed | Antigenicity and receptor-binding ability of recombinant SARS coronavirus spike protein |
title_short | Antigenicity and receptor-binding ability of recombinant SARS coronavirus spike protein |
title_sort | antigenicity and receptor-binding ability of recombinant sars coronavirus spike protein |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7111049/ https://www.ncbi.nlm.nih.gov/pubmed/14706633 http://dx.doi.org/10.1016/j.bbrc.2003.11.180 |
work_keys_str_mv | AT hotinyun antigenicityandreceptorbindingabilityofrecombinantsarscoronavirusspikeprotein AT wushihlu antigenicityandreceptorbindingabilityofrecombinantsarscoronavirusspikeprotein AT chengshinei antigenicityandreceptorbindingabilityofrecombinantsarscoronavirusspikeprotein AT weiyenchiao antigenicityandreceptorbindingabilityofrecombinantsarscoronavirusspikeprotein AT huangshanping antigenicityandreceptorbindingabilityofrecombinantsarscoronavirusspikeprotein AT hsiangchienyun antigenicityandreceptorbindingabilityofrecombinantsarscoronavirusspikeprotein |